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Abstract 
An  84  year-old  gentleman  presented  with
abdominal distension, anorexia and occasion-
al  epigastric  pain  over  a  four-week  period.
Blood  parameters  revealed  a  hypochromic
microcytic  anaemia.  Both  CT  and  US  scan
identified ascites and a mass in the left upper
quadrant. An ascitic tap was performed identi-
fying bloody ascites and the presence of reac-
tive mesothelial cells on cytology. A subsequent
laparotomy  and  splenectomy  was  performed.
Histology  of  the  resected  spleen  revealed  a
Grade 2 follicular lymphoma (Figure 2). The
patient had an uneventful postoperative recov-
ery and was well at 6 months follow up. The
spleen is an organ with an important immuno-
logical function. Primary splenic involvement
occurs in less than 1% of non-hodgkin’s lym-
phoma.  Symptoms  of  primary  splenic  lym-
phoma  (PSL)  include  pyrexia,  weight-loss,
night sweats, generalised weakness and left
upper  quadrant  pain  secondary  to  spleno  -
megaly. Ascites is a rare presenting feature of
PSL. This report illustrates a case of primary
splenic  lymphoma  which  poses  diagnostic
challenges  for  the  pathologist  and  clinician
and ultimately requires definitive splenectomy
to confirm a diagnosis.
Introduction
Primary splenic lymphoma (PSL) is a rare
condition occurring in less than 1% of non-
Hodgkin’s lymphoma. PSL often poses a diag-
nostic dilemma and symptoms include pyrexia,
weight-loss, night sweats, generalised weak-
ness and left upper quadrant pain secondary to
splenomegaly.  This  case  report  highlights  a
case of primary splenic lymphoma in an elder-
ly gentleman and illustrates the management
of such a case.
Case Report
An 84 year-old gentleman presented to the
emergency department with a four-week histo-
ry  of  abdominal  distension  and  associated
anorexia with occasional epigastric pain and
dysnpoea. Of note, he had a background histo-
ry of rheumatoid arthritis. On examination his
abdomen was soft but distended with ascites.
No abdominal masses were palpable and the
examination was otherwise normal. 
Bloodwork revealed a hypochromic, micro-
cytic anaemia, with a slightly elevated CRP and
LDH. Bone marrow biopsy and myeloma screen
were negative. Trans-thoracic echo was essen-
tially  normal  with  an  ejection  fraction  of
approximately  50%.  A  colonoscopy  was  per-
formed and showed sigmoid diverticular dis-
ease.  Abdominal  ultrasound  demonstrated
ascites and a 10 cm mass in the left upper
quadrant  related  to  the  upper  border  of  the
spleen. A subsequent CT scan also identified
ascites and a left upper quadrant mass with
celiac lymphadenopathy and bilateral pleural
effusions (Figure 1).
An ascitic tap was performed and yielded a
bloody aspirate. The albumin level of the ascites
was 29 g/L, with a total protein content of 52 g/L,
fluid  LDH  of  303  U/L  and  amylase  of  15U/L.
Cytology  identified  reactive  mesothelial  cells
and a cell-block yielded a predominantly epithe-
lial cell population. At this stage, the patient
began to experience worsening abdominal dis-
comfort due to the increasing abdominal disten-
sion. A laparoscopy was performed, at which an
enlarged spleen and copious bloody ascites was
noted. No active haemorrhage was identified
and  there  was  no  evidence  of  peritoneal  or
omental disease. All other intra-abdominal vis-
cera were normal. Three litres of ascitic fluid
was  drained  in  an  effort  to  obtain  definitive
cytology. Again, only reactive mesothelial cells
were identified. The ascitic fluid reaccumulated
within  one  week,  once  again  causing  severe
abdominal discomfort and following a full dis-
cussion with the patient and his family, an elec-
tive splenectomy was planned. At laparotomy, a
large splenic mass, involving the left crus, left
diaphragmatic dome, stomach and splenic flex-
ure of the colon was visualised. The mass was
completely resected and three litres of bloody
ascitic fluid was drained. 
The  resected  spleen  weighed  585  g  and
measured  140  mm  ﾥ  100  mm  ﾥ  100  mm.
Histology showed the splenic parenchyma to
be effaced by a lymphoid infiltrate, which was
CD20 positive, indicative of a B cell lineage.
CD10 was also positive. The appearances were
consistent with a low-grade, non-Hodgkin's B-
cell follicular lymphoma, with a focus of trans-
formation to high-grade lymphoma or possibly
a  composite  lymphoma  (i.e.  non-Hodgkin’s
plus  Hodgkin's  lymphoma).  Following  expert
second opinion, a final diagnosis of Grade 2
follicular  lymphoma  with  areas  of  Grade  3b
cytology was confirmed. The patient made an
uneventful recovery and was discharged eight
days post-operatively, without reaccumulation
of  the  ascites.  He  was  entirely  well  at  six-
month  out-patient  review  and  refused  any
form of adjuvant treatment.
Discussion
Primary Splenic lymphoma (PSL) is a rare
condition,  representing  less  than  1%  of  non-
Hodgkin’s lymphoma (NHL).1The spleen may be
the primary site of the lymphoma or it may be an
element of disseminated malignancy. PSL can be
difficult to diagnose as half of all patients with
Hodgkin’s Disease and one third of those with
non-Hodgkin’s lymphoma have splenic involve-
ment. Similarly, the definition of PSL is some-
what controversial. The case we report corre-
sponds with the definition by Das Gupta et al,
who describe PSL as a lymphoma only involving
the spleen and hilar lymph nodes, but not the
liver or other sites.2 In order for the diagnosis to
be confirmed there must be a six-month relapse-
free period following splenectomy. Definitions
vary, however. Skarin et al suggest that PSL is
any  lymphoma  with  splenic  involvement  in
which splenomegaly is the dominant feature.3
Symptoms of PSL include pyrexia, weight-loss,
night  sweats,  generalised  weakness  and  left
upper quadrant pain secondary to splenomegaly.
Cytopenia can also be a presenting feature and
significant laboratory findings include elevated
ESR and b2 microglobulin.4 The principal clini-
cal finding is splenomegaly, which in this partic-
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ular case was impossible to demonstrate, due to
the gross ascites. To our knowledge, this is the
first  reported  case  of  PSL  presenting  with
ascites. The most common appearance of PSL on
diagnostic  imaging  studies  is  of  hypodense
splenic lesions on contrast enhanced CT scans
or hypoechoic lesions on ultrasound.5 Contrast
enhanced ultrasound may also prove useful in
evaluating splenic lesions.6 MRI is also a useful
tool  for  identifying  and  characterizing  focal
splenic lesions.7 The differential diagnosis for
such appearances is broad and splenectomy is
often required for definitive diagnosis. Kraus et
al. demonstrated that whilst malignancy is the
most  common  diagnosis  in  patients  with  a
splenic mass, splenectomy is frequently refused
by  patients  and  in  such  cases  radiologically-
guided, percutaneous biopsy may offer an alter-
native modality to diagnose and histologically
subtype splenic lymphoma.8 Disease staging of
PSL has been described by Ahmann and Kiely.9
Stage I refers to disease confined to the spleen;
Stage II implies involvement of the spleen and
hilar lymph nodes and Stage III refers to extra-
splenic nodal or hepatic involvement. 5-year sur-
vival is relatively poor, with a 31% overall sur-
vival for all groups.9Kehoe et al.,with a series of
21 patients over a 5-year period, demonstrated a
combined survival rate of 43% for Stage I and II
disease, but just 14% for Stage III.10 However, as
both of these studies are quite old, there is a
need for an updated study to take into account
novel  imaging  modalities  and  therapeutic
options.  Xiros et al. maintain that the median
survival  after  diagnostic  splenectomy  is  24
months regardless of disease stage or adjuvant
chemotherapeutic regimen.11 Treatment for PSL
sparks debate due to the lack of clinical trials.
Possible treatment modalities include splenecto-
my, local radiotherapy and systemic chemother-
apy. Splenectomy is often both diagnostic and
therapeutic. Local radiotherapy is considered for
those in whom splenectomy is not an option.
Morel et al. stated that early splenectomy can
improve  survival  for  those  patients  in  whom
cytopenia improves after surgery and those who
tolerate adjuvant chemothe  rapy.4 Musteata et al.
after looking at 104 patients with primary low
grade NHL of the spleen concluded that early
splenectomy  along  with  combination
chemotherapy is the optimum treatment due to
higher  rates  of  remission,  a  more  prolonged
duration of remission and better overall survival
rates  when  compared  with  splenectomy  or
splenectomy with single agent chemotherapy.12
The CHOP regimen appears to be the most wide-
ly  accepted  chemotherapy  regimen  for  PSL,
according  to  the  individual  cases  despite  the
lack of clinical trials on the subject.  
Conclusion
In summary, PSL is a rare condition which
can be difficult to diagnose. Splenectomy offers
both definitive histological diagnosis and thera-
peutic resection and represents the mainstay of
treatment.  Adjuvant  chemotherapy  and  radio-
therapy may be of use and outcomes, unsurpris-
ingly, are far superior with early stage (I & II)
disease. When splenectomy is combined with
combination chemotherapy, outcomes in terms
of remission and survival are improved.
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Case Report
Figure  1.  Computed  tomography  of  the
abdomen showing an enlarged spleen and
the presence of ascites
Figure  2.  Photograph  of  histology  slide
displaying the lymphoma at 10X magnifi-
cation.